Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas and Cytokinetics agree new collaboration

Astellas and Cytokinetics agree new collaboration

27th June 2013

Astellas has announced a collaboration with fellow healthcare company Cytokinetics that will focus on the research, development and commercialisation of skeletal muscle activators.

The two companies will carry out joint research into skeletal muscle activation with the aim of advancing the creation of novel therapies for diseases and medical conditions associated with muscle weakness.

Focusing on expanding emerging opportunities in skeletal muscle contractility, the research will identify and optimise fast skeletal troponin activators and other potential novel mechanisms, leveraging the expertise of both organisations.

Astellas will have the exclusive rights to develop and commercialise drug candidates arising from this collaboration.

Yoshihiko Hatanaka, Astellas' president and chief executive officer, said: "This new collaboration illustrates Astellas' important commitment to enhance its abilities to generate innovative drugs by deploying cutting-edge science, accessing distinguished internal and external talent, and utilising the optimal research environment."

Earlier this week, Astellas announced that its advanced prostate cancer drug Xtandi – developed alongside Medivation – has received European regulatory approval.ADNFCR-8000103-ID-801604810-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.